Literature DB >> 19332325

Alteration of epileptogenesis genes.

Amy R Brooks-Kayal1, Yogendra H Raol, Shelley J Russek.   

Abstract

Retrospective studies suggest that precipitating events such as prolonged seizures, stroke, or head trauma increase the risk of developing epilepsy later in life. The process of epilepsy development, known as epileptogenesis, is associated with changes in the expression of a myriad of genes. One of the major challenges for the epilepsy research community has been to determine which of these changes contributes to epileptogenesis, which may be compensatory, and which may be noncontributory. Establishing this for any given gene is essential if it is to be considered a therapeutic target for the prevention or treatment of epilepsy. Our laboratories have examined alterations in gene expression related to inhibitory neurotransmission that have been proposed as contributing factors in epileptogenesis. The GABA(A) receptor mediates most fast synaptic inhibition, and changes in GABA(A) receptor subunit expression and function have been reported in adult animals beginning immediately after prolonged seizures (status epilepticus [SE]) and continue as animals become chronically epileptic. Prevention of GABA(A) receptor subunit changes after SE using viral gene transfer inhibits development of epilepsy in an animal model, suggesting that these changes directly contribute to epileptogenesis. The mechanisms that regulate differential expression of GABA(A) receptor subunits in hippocampus after SE have recently been identified, and include the CREB-ICER, JAK-STAT, BDNF, and Egr3 signaling pathways. Targeting signaling pathways that alter the expression of genes involved in epileptogenesis may provide novel therapeutic approaches for preventing or inhibiting the development of epilepsy after a precipitating insult.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19332325      PMCID: PMC2700027          DOI: 10.1016/j.nurt.2009.01.019

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  64 in total

Review 1.  The GABA-A receptor gene family: new targets for therapeutic intervention.

Authors:  P J Whiting
Journal:  Neurochem Int       Date:  1999-05       Impact factor: 3.921

Review 2.  A road map for those who don't know JAK-STAT.

Authors:  David S Aaronson; Curt M Horvath
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

3.  Glial cell line-derived neurotrophic factor modulates kindling and activation-induced sprouting in hippocampus of adult rats.

Authors:  Songlin Li; Bin Xu; David Martin; Ronald J Racine; Margaret Fahnestock
Journal:  Exp Neurol       Date:  2002-11       Impact factor: 5.330

4.  Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone.

Authors:  Lyudmila Burdelya; Robyn Catlett-Falcone; Alexander Levitzki; Fengdong Cheng; Linda B Mora; Eduardo Sotomayor; Domenico Coppola; JiaZhi Sun; Said Sebti; William S Dalton; Richard Jove; Hua Yu
Journal:  Mol Cancer Ther       Date:  2002-09       Impact factor: 6.261

5.  Seizure suppression by GDNF gene therapy in animal models of epilepsy.

Authors:  Irene Kanter-Schlifke; Biljana Georgievska; Deniz Kirik; Merab Kokaia
Journal:  Mol Ther       Date:  2007-03-27       Impact factor: 11.454

6.  Brain-derived neurotrophic factor (BDNF)-induced synthesis of early growth response factor 3 (Egr3) controls the levels of type A GABA receptor alpha 4 subunits in hippocampal neurons.

Authors:  Daniel S Roberts; Yinghui Hu; Ingrid V Lund; Amy R Brooks-Kayal; Shelley J Russek
Journal:  J Biol Chem       Date:  2006-08-10       Impact factor: 5.157

7.  Anticonvulsant activity of a nonpeptide galanin receptor agonist.

Authors:  Külliki Saar; Andrey M Mazarati; Riina Mahlapuu; Gerd Hallnemo; Ursel Soomets; Kalle Kilk; Sven Hellberg; Margus Pooga; Bo-Ragnar Tolf; Tiejun S Shi; Tomas Hökfelt; Claude Wasterlain; Tamas Bartfai; Ulo Langel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

Review 8.  Galnon--a low-molecular weight ligand of the galanin receptors.

Authors:  Ulla Sollenberg; Tamas Bartfai; Ulo Langel
Journal:  Neuropeptides       Date:  2005-02-02       Impact factor: 3.286

9.  Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy.

Authors:  Francesco Noè; Allan-Hermann Pool; Jari Nissinen; Marco Gobbi; Ross Bland; Massimo Rizzi; Claudia Balducci; Francesco Ferraguti; Gunther Sperk; Matthew J During; Asla Pitkänen; Annamaria Vezzani
Journal:  Brain       Date:  2008-05-13       Impact factor: 13.501

10.  Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor.

Authors:  C A Molina; N S Foulkes; E Lalli; P Sassone-Corsi
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

View more
  26 in total

1.  Role of signal transducer and activator of transcription-3 in up-regulation of GFAP after epilepsy.

Authors:  Zucai Xu; Tao Xue; Zuxia Zhang; Xuefeng Wang; Ping Xu; Jun Zhang; Xianze Lei; Yuqin Li; Yunlan Xie; Liang Wang; Min Fang; Yangmei Chen
Journal:  Neurochem Res       Date:  2011-08-11       Impact factor: 3.996

2.  Decrease in CA3 inhibitory network activity during Theiler's virus encephalitis.

Authors:  R M Smeal; R Fujinami; H S White; K S Wilcox
Journal:  Neurosci Lett       Date:  2015-10-23       Impact factor: 3.046

Review 3.  Is epilepsy a preventable disorder? New evidence from animal models.

Authors:  Kathryn A Giblin; Hal Blumenfeld
Journal:  Neuroscientist       Date:  2010-06       Impact factor: 7.519

Review 4.  The role of gap junction channels during physiologic and pathologic conditions of the human central nervous system.

Authors:  Eliseo A Eugenin; Daniel Basilio; Juan C Sáez; Juan A Orellana; Cedric S Raine; Feliksas Bukauskas; Michael V L Bennett; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-23       Impact factor: 4.147

5.  Brain-derived neurotrophic factor uses CREB and Egr3 to regulate NMDA receptor levels in cortical neurons.

Authors:  Julia H Kim; Daniel S Roberts; Yinghui Hu; Garrick C Lau; Amy R Brooks-Kayal; David H Farb; Shelley J Russek
Journal:  J Neurochem       Date:  2011-11-28       Impact factor: 5.372

Review 6.  GABAergic transmission in temporal lobe epilepsy: the role of neurosteroids.

Authors:  Suchitra Joshi; Karthik Rajasekaran; Jaideep Kapur
Journal:  Exp Neurol       Date:  2011-11-04       Impact factor: 5.330

7.  Water maze experience and prenatal choline supplementation differentially promote long-term hippocampal recovery from seizures in adulthood.

Authors:  Sarah J E Wong-Goodrich; Melissa J Glenn; Tiffany J Mellott; Yi B Liu; Jan K Blusztajn; Christina L Williams
Journal:  Hippocampus       Date:  2010-03-15       Impact factor: 3.899

Review 8.  Altered GABA(A) receptor expression during epileptogenesis.

Authors:  Marco I González; Amy Brooks-Kayal
Journal:  Neurosci Lett       Date:  2011-03-03       Impact factor: 3.046

Review 9.  Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction.

Authors:  Ethan M Goldberg; Douglas A Coulter
Journal:  Nat Rev Neurosci       Date:  2013-04-18       Impact factor: 34.870

10.  Myo-inositol treatment and GABA-A receptor subunit changes after kainate-induced status epilepticus.

Authors:  Revaz Solomonia; Nana Gogichaishvili; Maia Nozadze; Eka Lepsveridze; David Dzneladze; Tamar Kiguradze
Journal:  Cell Mol Neurobiol       Date:  2012-09-18       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.